Biocon Biologics wraps up integration of Viatris’ biosimilars business in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the integration of Viatris’ biosimilars business across 31 European countries. This significant achievement follows the acquisition of the majority of Viatris’ global biosimilar business in November 2022 and marks Biocon Biologics as a leading player in the biosimilars industry.
Biocon Biologics’ European Portfolio and Global Presence
In Europe, Biocon Biologics’ portfolio includes seven biosimilars: Insulin Aspart, Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept. Globally, the company boasts a robust pipeline of 20 products in various therapeutic areas, serving over 5.7 million patients annually. This expansion is a testament to Biocon Biologics’ commitment to providing accessible, high-quality therapies worldwide.
Leadership Comments on the Integration
Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the importance of this integration in expanding access to life-saving treatments in Europe. Jozef Belcik, Head of Commercial Europe & JANZ at Biocon Biologics, also highlighted the company’s leadership in advancing biosimilars and its dedication to innovation in the pharmaceutical industry.
Biocon Biologics’ Market Reach Post-Acquisition
Post-acquisition from Viatris, Biocon Biologics and its partners will commercialize biosimilar products in various European countries, including major markets like Germany, France, Italy, and the United Kingdom. This expansion showcases Biocon Biologics’ growing influence in the global healthcare market and its role in shaping the future of biosimilar treatments.
The integration of Viatris’ biosimilars into Biocon Biologics’ portfolio in Europe represents a strategic move in the biotechnology sector, enhancing the company’s ability to address diverse patient needs and strengthen its position as a global healthcare leader.